[Corrigendum] TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma

• Authors:
  • Song Ye
  • Xin-Yi Zhao
  • Xiao-Ge Hu
  • Tang Li
  • Qiu-Ran Xu
  • Huan-Ming Yang
  • Dong-Sheng Huang
  • Liu Yang

• View Affiliations

  
  Affiliations: Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang university, Hangzhou, Zhejiang 310003, P.R. China, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang university School of Medicine, Hangzhou, Zhejiang 310003, P.R. China, Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Key Laboratory of Gastroenterology of Zhejiang Province, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang 310014, P.R. China, Beijing Genomics Institute (BGI)-Shenzhen, Shenzhen, Guangdong 518103, P.R. China
• Published online on: September 19, 2022     https://doi.org/10.3892/or.2022.8411
• Article Number: 196

• Copyright : © Ye et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Article